Management of hepatitis B in special patient populations

Clinics in Liver Disease

Volumn 14, Issue 3, 2010, Pages 505-520

  Wang, Hank S ^a   Han, Steven Huy B ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Acute liver failure; Hepatitis B and C coinfection; Hepatitis B and HIV coinfection; Immunosuppression associated hepatitis B reactivation

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; INFLIXIMAB; INTERFERON; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISONE; RIBAVIRIN; RITUXIMAB; TELBIVUDINE; TENOFOVIR; VINCRISTINE; ANTIVIRUS AGENT;

ABSENCE OF SIDE EFFECTS; DELTA AGENT HEPATITIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; HEART TRANSPLANTATION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY TRANSPLANTATION; LIVER FAILURE; LOW DRUG DOSE; MIXED INFECTION; MONOTHERAPY; NONHUMAN; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS REACTIVATION; COMPLICATION; DRUG EFFECTS; HEPATITIS B VIRUS; HEPATITIS D; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LIVER FAILURE, ACUTE; PHYSIOLOGY; SECONDARY PREVENTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; HEART TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS D; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSION; INTERFERON-ALPHA; KIDNEY TRANSPLANTATION; LIVER FAILURE, ACUTE; RECURRENCE; SECONDARY PREVENTION;

EID: 77954643354     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2010.05.002     Document Type: Review

References (88)

1. Polson J., Lee W.M. AASLD position paper: the management of acute liver failure. Hepatology 2005, 41:1179-1197.
2. Ostapowicz G., Fontana R.J., Schiodt F.V., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002, 137:947-954.
3. Lee H. Acute liver failure related to hepatitis B virus. Hepatol Res 2008, 38:S9-S13.
4. Shakil A.O., Kramer D., Mazariegos G.V., et al. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl 2000, 6:163-169.
5. Steinmuller T., Seehofer D., Rayes N., et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002, 35:1528-1535.
6. Lai C.L., Chien R.N., Leung N.W., et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1999, 329:61-68.
7. Fontanta R.J. Management of patients with decompensated HBV cirrhosis. Semin Liver Dis 2003, 23:89-100.
8. Leifeled L., Cheng S., Ramakers J., et al. Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B. Hepatology 2002, 36:1001-1008.
9. Schmilovitz-Weiss H., Ben-Ari Z., Sikuler E., et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int 2004, 24:547-551.
10. Tillman H.L., Hadem J., Leifeld L., et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006, 13:256-263.
11. Kumar M., Satapathy S., Monga R. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007, 45:97-101.
12. Seremba E., Sanders C.M., Jain M.K., et al. Use of nucleoside analogues in HBV-related acute liver failure. Hepatology 2007, 46:276a.
13. Wai C.T., Fontana R.J., Polson J., et al. Clinical outcome and virologic characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat 2005, 12:192-198.
14. Peters M.G. Special populations with hepatitis B virus infection. Hepatology 2009, 49(Suppl 5):S146-S155.
15. Shih C.M., Chen C.M., Chen S.Y., et al. Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation. J Virol 1995, 69(2):1160-1171.
16. Schüttler C.G., Fiedler N., Schmidt K., et al. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 2002, 37:855-862.
17. Pontisso P., Gerotto M., Ruvoletto M.G., et al. Hepatitis C genotypes in patients with dual hepatitis B and C virus infection. J Med Virol 1996, 48:157-160.
18. Raimondo G., Brunetto M.R., Pontisso P., et al. Longitudinal evaluation reveals a complex spectrum of virologic profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006, 43(1):100-107.
19. Zarski J.P., Bohn B., Bastie A., et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998, 28:27-33.
20. Gaeta G.B., Stornaiuolo G., Precone D.F., et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol 2003, 39(6):1036-1041.
21. Kaklamani E., Trichopoulos D., Tzonou A., et al. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA 1991, 265:1974-1976.
22. Chiaramonte M., Stroffolini T., Vian A., et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999, 85:2132-2137.
23. Chu C.J., Lee S.D. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions, and treatment. J Gastroenterol Hepatol 2008, 23(4):512-520.
24. Liu C.J., Chen P.J., Lai M.Y., et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003, 37(3):568-576.
25. Hung C.H., Lee C.M., Lu S.N., et al. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol 2005, 20:727-732.
26. Chuang W.L., Dai C.Y., Chang W.Y., et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther 2005, 10:125-133.
27. Liu C.J., Chuang W.L., Lee C.M., et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009, 136:496-504.
28. Marrone A., Zampino R., D'Onofrio M., et al. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. J Hepatol 2004, 41(6):1064-1065.
29. Liaw Y.F., Chen Y.C., Sheen I.S., et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004, 126(4):1024-1029.
30. Lau D.T., Kleiner D.E., Park Y., et al. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology 1999, 117(5):1229-1233.
31. Rosina F., Pintus C., Meschievitz C., et al. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991, 13(6):1052-1056.
32. Farci P., Roskams T., Chessa L., et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004, 126(7):1740-1749.
33. Erhardt A., Gerlich W., Starke C., et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006, 26(7):805-810.
34. Niro G.A., Ciancio A., Gaeta G.B., et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006, 44:713-720.
35. Castelnau C., Le Gal F., Ripault M.P., et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up. Hepatology 2006, 44:728-735.
36. Ferenci P., Formann E., Romeo R. Successful treatment of chronic hepatitis D with a short course of peginterferon alfa-2a. Am J Gastroenterol 2005, 100:1626-1627.
37. Yurdaydin C., Wedemeyer H., Dalekos G., et al. A multicenter randomised study comparing the efficacy of pegylated interferon alfa-2A plus adefovir dipivoxil vs. pegylated interferon alfa-2A plus placebo vs. adefovir dipovoxil for the treatment of chronic delta hepatitis: the intervention trial (HID-IT). Hepatology 2006, 41(Suppl 1):230A. [abstract].
38. Yurdaydin C., Bozkaya H., Onder F.O., et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat 2008, 15(4):314-321.
39. Alter M.J. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006, 44(Suppl 1):S6-S9.
40. Diop-Ndiaye H., Toure-Kane C., Etard J.F., et al. Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol 2008, 80:1332-1336.
41. Bodsworth N.J., Cooper D.A., Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B carrier state. J Infect Dis 1991, 163:1138-1140.
42. Gilson R.J., Hawkins A.E., Beecham M.R., et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997, 11:597-606.
43. Colin J.F., Cazals-Hatem D., Loriot M.A., et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999, 29:1306-1310.
44. Biggar R.J., Goedert J.J., Hoofnagle J. Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV. N Engl J Med 1987, 316:630.
45. Thio C.L., Seaberg E.C., Skolasky R.L., et al. HIV-1, hepatitis B virus and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002, 360:1921-1926.
46. Grob P., Jilg W., Bornhak H., et al. Serological pattern " anti-HBc alone": report on a workshop. J Med Virol 2000, 62:450-455.
47. Hofer M., Joller-Jemelka H.I., Grob P.J., et al. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998, 17:6-13.
48. Keefe E.B., Dieterich D.T., Han S.H., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008, 6:1315-1341.
49. Thio C.L. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009, 49:S138-S145.
50. Kaplan J.E., Benson C., Holmes K.H., et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2009, 58:1.
51. Matthews G.V., Dore G.J. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2007, 21:777-778.
52. McMahon M.A., Jilek B.L., Brennan T.P., et al. The HBV drug entecavir--effects on HIV-1 replication and resistance. N Engl J Med 2007, 356:2614-2621.
53. Chung R.T., Andersen J., Volberding P., et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451-459.
54. Delaugerre C., Marcelin A.G., Thibault V., et al. Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 2002, 46:1586.
55. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2008, Department of Health and Human Services, Bethesda (MD), p. 1-139.
56. Hoofnagle J.H. Reactivation of hepatitis B. Hepatology 2009, 49:S156-S165.
57. Yeo W., Chan P.K., Zhong S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000, 62:299-307.
58. Lok A.S., Liang R.H., Chiu E.K., et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991, 100:182-188.
59. Loomba R., Rowley A., Wesley R., et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008, 148:519-528.
60. Yeo W., Zee B., Zhong S., et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004, 90:1306-1311.
61. Tur-Kaspa R., Shaul Y., Moore D.D., et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988, 167:630-633.
62. McMillan J.S., Shaw T., Angus P.W., et al. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995, 22(1):36-43.
63. Yeo W., Chan T.C., Leung N.W., et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009, 27(4):605-611.
64. Esteve M., Saro C., González-Huix F., et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004, 53:1363-1365.
65. Lau G.K., Yiu H.H., Fong D.Y., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125:1742-1749.
66. Yeo W., Chan P.K., Ho W.M., et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004, 22:927-934.
67. Sumethkul V., Ingsathit A., Jirasiritham S. Ten-year follow-up of kidney transplantation from hepatitis B surface antigen-positive donors. Transplant Proc 2009, 41(1):213-215.
68. Lau G.K., Leung Y.H., Fong D.Y., et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002, 99:2324-2330.
69. Fornairon S., Pol S., Legendre C., et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996, 62(2):297-299.
70. Ridruejo E., Brunet Mdel R., Cusumano A., et al. HBsAg as predictor of outcome in renal transplant patients. Medicina (B Aires) 2004, 64(5):429.
71. Harnett J.D., Zeldis J.B., Parfrey P.S., et al. Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation 1987, 44(3):369-376.
72. Lunel F., Cadranel J.F., Rosenheim M., et al. Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology 2000, 119(4):1064-1074.
73. Wedemeyer H., Pethig K., Wagner D., et al. Long-term outcome of chronic hepatitis B in heart transplant recipients. Transplantation 1998, 66(10):1347-1353.
74. Magnone M., Holley J.L., Shapiro R., et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995, 59(7):1068-1070.
75. Rakela J., Wooten R.S., Batts K.P., et al. Failure of interferon to prevent recurrent hepatitis B infection in hepatic allograft. Mayo Clin Proc 1989, 64(4):429-432.
76. Chan T.M., Wu P.C., Li F.K., et al. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998, 115(1):177-181.
77. Liu C.J., Lai M.Y., Lee P.H., et al. Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience. J Gastroenterol Hepatol 2001, 16(9):1001-1008.
78. Rostaing L., Henry S., Cisterne J.M., et al. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997, 64(11):1624-1627.
79. Wang S.S., Chou N.K., Chi N.H., et al. Successful treatment of hepatitis B virus infection with Lamivudine after heart transplantation. Transplant Proc 2006, 38(7):2138-2140.
80. Potthoff A., Tillmann H.L., Bara C., et al. Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. J Viral Hepat 2006, 13(11):734-741.
81. Gane E., Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002, 74(4):427-437.
82. Lau D.T., Khokhar M.F., Doo E., et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000, 32(4 Pt 1):828-834.
83. Han D.J., Kim T.H., Park S.K., et al. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001, 71(3):387-394.
84. Yeo W., Steinberg J.L., Tam J.S., et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999, 59(3):263-269.
85. Lau G.K., Lie A., Liang R. Prophylactic lamivudine therapy for hepatitis B patients undergoing immunosuppressive therapy. Blood 2002, 100(8):3054.
86. Chan T.M., Fang G.X., Tang C.S., et al. Pre-emptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002, 36(5):1246-1252.
87. Liaw Y.F., Leung N.W., Chang T.T., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000, 119(1):172-180.
88. Kohrt H.E., Ouyang D.L., Keeffe E.B. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis 2007, 11:965-991.